Shares of Grace Therapeutics Inc. (GRCE) reached a 52-week high of $4.12 during intraday trading yesterday, which reflects a gain of nearly 65% over the past three months.
Grace Therapeutics, a late-stage biopharmaceutical company focused on rare diseases, is advancing its lead clinical candidate, GTx-104, a novel injectable formulation of nimodipine, in the treatment of aneurysmal Subarachnoid Hemorrhage (aSAH).
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.